Date | Time | Source | Announcement |
---|---|---|---|
01 Dec 2003 | 10:56 AM | Holding(s) in Company | |
27 Nov 2003 | 07:00 AM | Research Update | |
24 Nov 2003 | 09:12 AM | Blocklisting Interim Review | |
13 Nov 2003 | 07:00 AM | Preclinical update | |
10 Nov 2003 | 05:53 PM | Holding(s) in Company | |
05 Nov 2003 | 08:37 AM | Holding(s) in Company | |
05 Nov 2003 | 08:29 AM | Holding(s) in Company | |
29 Oct 2003 | 04:25 PM | Holding(s) in Company | |
27 Oct 2003 | 05:29 PM | Result of Equity Issue | |
24 Oct 2003 | 09:51 AM | Research Update | |
23 Oct 2003 | 08:47 AM | Director Shareholding | |
02 Oct 2003 | 01:10 PM | Result of EGM | |
16 Sep 2003 | 07:01 AM | Rights Issue | |
16 Sep 2003 | 07:00 AM | Interim Results | |
09 Sep 2003 | 07:00 AM | Retinostat Agreement | |
28 Aug 2003 | 07:00 AM | Re Joint Venture | |
20 Aug 2003 | 07:00 AM | Notice of Results | |
13 Aug 2003 | 07:00 AM | LentiVector Patent Update | |
14 Jul 2003 | 07:00 AM | TroVax Update | |
03 Jul 2003 | 07:00 AM | Research Update | |
23 Jun 2003 | 07:00 AM | Update on ProSavin | |
27 May 2003 | 03:25 PM | Blocklisting Interim Review | |
22 May 2003 | 10:16 AM | Additional Listing | |
20 May 2003 | 07:00 AM | TroVax Update | |
06 May 2003 | 07:00 AM | Data on RetinoStat | |
23 Apr 2003 | 02:43 PM | Holding(s) in Company | |
15 Apr 2003 | 07:00 AM | AGM Statement | |
18 Mar 2003 | 07:00 AM | Option Agreement | |
04 Mar 2003 | 07:00 AM | Wyeth Collaboration Update | |
04 Mar 2003 | 07:00 AM | Final Results | |
03 Mar 2003 | 07:00 AM | TroVax to Enter Phase II | |
12 Feb 2003 | 09:09 AM | Notice of Results | |
11 Feb 2003 | 07:00 AM | Grant Awarded | |
28 Jan 2003 | 07:00 AM | Joint Programme Agreed | |
20 Jan 2003 | 04:01 PM | Holding(s) in Company | |
17 Jan 2003 | 04:47 PM | Holding(s) in Company | |
06 Jan 2003 | 07:00 AM | Research Agreement | |
17 Dec 2002 | 11:43 AM | Grant Awarded | |
25 Nov 2002 | 07:00 AM | Change of Adviser | |
14 Nov 2002 | 10:47 AM | New Appointment | |
08 Nov 2002 | 09:00 AM | Update on Clinical Plans | |
01 Nov 2002 | 02:12 PM | Directorate Change | |
24 Oct 2002 | 08:59 AM | New Development Partner | |
19 Sep 2002 | 03:02 PM | Director Shareholding | |
17 Sep 2002 | 12:16 PM | Director Shareholding | |
11 Sep 2002 | 03:26 PM | Director Shareholding | |
29 Aug 2002 | 03:35 PM | Director Shareholding | |
28 Aug 2002 | 07:00 AM | Interim Results | |
27 Aug 2002 | 04:10 PM | Holding(s) in Company | |
13 Aug 2002 | 11:28 AM | Notice of Results |
Oxford Biomedica is a company that specialises in cell and gene therapy, and is a leader in the development of gene-based medicines. They work with pharmaceutical and biotechnology companies to develop and manufacture viral vectors, including lentivirus, adeno-associated virus, and adenoviral vectors.
Headquartered in Oxford, Oxford Biomedica has manufacturing facilities in Oxfordshire, UK, Lyon and Strasbourg, France, and near Boston, MA, US.
Oxford Biomedica share price listed in London under the ticker OXB at 2,570p.